The primary endpoint was the percentage change in body weight from baseline to week 48, with secondary endpoints including the proportion of participants achieving clinically meaningful weight loss thresholds and changes in cardiometabolic risk markers
Erythropoietic Protoporphyria (EPP) Melanotan-1 Melanotan-1 (afamelanotide/Scenesse) is the only EMA-approved treatment for EPP, with Phase 3 RCT data showing increased pain-free sun exposure and improved quality of life Vitiligo Adjunct Therapy Melanotan-1 Small RCT data shows faster and deeper repigmentation when afamelanotide implants are combined with NB-UVB phototherapy compared to phototherapy alone Photoprotection Research Melanotan-1 Melanotan-1 enhances eumelanin production and DNA repair mechanisms with a favorable safety profile established across multiple clinical trials Melanocortin Receptor Pharmacology Melanotan-2 Melanotan-2 nonselective receptor profile makes it a useful research tool for studying MC1R through MC5R signaling pathways Sexual Dysfunction Research Melanotan-2 Melanotan-2 MC4R activation produces erectogenic effects
Hes starting his treatment
It will conclude in 2026 and provide insight for further investigations into the role GLP-1 agonists may offer in treating respiratory illnesses and overall immune responses
Significantly higher R voltage and significantly shortened QT-c interval were present in the combined treated hypothyroid group than in the L-thyroxine-treated hypothyroid group, as shown in Figure 2
"Plan members are encouraged to talk with their provider(s), who are able to help determine safe and effective care treatment options and plans." Right now, there is no lifetime maximum benefit set for these medications under Mayo Clinic's employee health insurance plan, which is offered through Medica
